A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

Clicks: 430
ID: 71489
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #2 of 43 articles by views in Neuro-Oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Ofranergene obadenovec (VB-111) is an anti-cancer viral therapy that demonstrated in a Phase-II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab.This pivotal phase-III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles q8W in combination with bevacizumab 10mg/Kg q2W (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS) and secondary endpoints were objective response rate (ORR) by RANO and Progression Free Survival (PFS).256 patients were enrolled at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination vs control arm (HR 1.20 [95% CI 0.91-1.59, p=0.19) and ORR was 27.3% versus 21.9% (P=0.26). A higher rate of grade 3-5 Adverse Events was reported in the combination arm (67% vs 40%) mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a post treatment febrile reaction.In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase-II results.
Reference Key
cloughesy2019aneurooncology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cloughesy, Timothy F;Brenner, Andrew;de Groot, John F;Butowski, Nicholas A;Zach, Leor;Campian, Jian L;Ellingson, Benjamin M;Freedman, Laurence S;Cohen, Yael C;Lowenton-Spier, Noa;Rachmilewitz Minei, Tamar;Shmueli, Shifra Fain;, ;Wen, Patrick Y;
Journal Neuro-Oncology
Year 2019
DOI
noz232
URL
Keywords
glioblastoma gene therapy anti-angiogenesis vb-111 viral immune-oncology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.